Session Information
-
WCLC 2022
2022 World Conference on Lung Cancer
As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2015
All times listed are in Vienna, Austria Time, CEST (UTC+2:00)
PL - Plenary
IBS - Interactive Breakfast Session (in-person attendees only)
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
P - Posters
EP - ePosters
WS - Workshops
LA – Lectureship Awards
IS - Industry Symposium
August 5 Fri
Aug 5 Saturday
August 6 Sat
Aug 6 Sunday
August 7 Sun
Aug 7 Monday
August 8 Mon
Aug 8 Tuesday
August 9 Tue
Aug 9
-
+
ES07 - Impact of Tumor Plasticity and Molecular/Immune Adaptations in Treatment Sensitivity and Resistance
- 12:00 - 13:00
- 8/07/2022
- Location: Strauss 1/2
- IASLC CME Accredited
- Type: Education Session
- Track: Tumor Biology and Biomarkers
- Moderators:Benjamin Besse, Yuko Minami
-
+
Session Moderator
12:50 - 13:00 | Presenter: Benjamin Besse
- Abstract
Loading... -
+
Session Moderator
12:50 - 13:00 | Presenter: Yuko Minami
- Abstract
Loading... -
+
ES07.01 - Session Introduction
12:00 - 12:01 | Presenter: Benjamin Besse
- Abstract
Loading... -
+
ES07.02 - Session Introduction
12:01 - 12:02 | Presenter: Yuko Minami
- Abstract
Loading... -
+
ES07.03 - NSCLC Persister Cells and Their Role in Treatment Resistance and Disease Progression
12:02 - 12:14 | Presenter: Trever Bivona
- Abstract
Loading... -
+
ES07.04 - Biological Role and Actionability of Molecular/Immune Alterations after Acquired Resistance to Single-Agent and Combination Therapies (Focus on EMT, Includes SCLC)
12:14 - 12:26 | Presenter: Sandra Ortiz-Cuaran
- Abstract
Loading... -
+
ES07.05 - Tumor Cell Plasticity and Histological/Molecular Changes: Focus On Transition from NSCLC to SCLC
12:26 - 12:38 | Presenter: Triparna Sen
- Abstract
Loading... -
+
ES07.06 - Biological Advances in SCLC: Molecular Subtypes, Anti-tumor Immune Responses and Impact on Therapeutics
12:38 - 12:50 | Presenter: Helmut Popper
- Abstract
Loading... -
+
ES07.07 - Live Q&A
12:50 - 13:00
- Abstract
Loading...
-
+
EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
-
+
EP08.01-090 - Association of Gender and Outcomes in Patients With Advanced NSCLC Treated With Immunotherapy Alone or in Combination With Chemotherapy Upfront.
Presenter: Teresa Gorria- Abstract
Loading... -
+
EP08.01-091 - Association of dNLR Score with Outcomes in Patients with Advanced NSCLC Under Immunotherapy Alone +/- Chemotherapy Upfront
Presenter: Teresa Gorria- Abstract
Loading...
-
+
EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
-
+
EP08.02-016 - Frontline and Post-Osimertinib Therapy for EGFR-mutant Advanced NSCLC: Treatment Patterns, Outcomes, Healthcare Use and Costs
Presenter: Benjamin Besse- Abstract
Loading... -
+
EP08.02-041 - NVL-520, a Highly Selective ROS1 Inhibitor, in Patients with Advanced ROS1-Positive Solid Tumors: The Phase 1/2 ARROS-1 Study
Presenter: Alexander Drilon- Abstract
Loading... -
+
EP08.02-173 - Treatment Patterns and Outcomes Among Patients With EGFR-mutant Advanced NSCLC in the Frontline and Post-Osimertinib Settings
Presenter: Joshua Sabari- Abstract
Loading...
-
+
P1.16 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- 17:00 - 19:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: Regular Poster
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
-
+
P1.16-02 - Clinical Utility of ctDNA in Advanced NSCLC at Diagnosis or Where Insufficient Tissue Was Available, Based on the ESMO ESCAT Scale
Presenter: Laura Mezquita- Abstract
Loading...
-
+
PL03 - Plenary 3: Presidential Symposium - Top Rated Abstracts (Live Streamed Session)
- 08:30 - 10:20
- 8/08/2022
- Location: Hall C1
- IASLC CME Accredited
- Type: Plenary
- Track: N/A
- Moderators:Heather Wakelee, Eric Lim
-
+
PL03.10 - Discussant
Presenter: Benjamin Besse- Abstract
Loading...
-
+
OA07 - Is There Still a Role for Chemotherapy Alone in the Management of NSCLC?
- 11:00 - 12:00
- 8/08/2022
- Location: Hall C7
- Not for CME Credit
- Type: Oral
- Track: Metastatic Non-small Cell Lung Cancer - Palliative Chemotherapy
- Moderators:Lubos Petruzelka, Pilar Garrido
-
+
OA07.06 - Second Line Treatment Outcomes After Progression on Immunotherapy Plus Chemotherapy (IO-CT) In Advanced Non-small Cell Lung Cancer (aNSCLC)
11:32 - 11:42 | Presenter: Edouard Auclin
- Abstract
Loading...
-
+
MA07 - Overcoming Resistance to EGFR Inhibitors
- 12:15 - 13:15
- 8/08/2022
- Location: Hall C7
- Not for CME Credit
- Type: Mini Oral
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Moderators:Dana Lucia Stanculeanu, Ross Soo
-
+
MA07.07 - Clinical/Molecular Profile of Patients with Non-small Cell Lung Cancer (NSCLC) with Incidental Pathogenic Germline Variants Detected in cfDNA
12:42 - 12:47 | Presenter: Laura Mezquita
- Abstract
Loading...
-
+
MA10 - Updates in Thymoma
- 14:45 - 15:45
- 8/08/2022
- Location: Hall C8
- Not for CME Credit
- Type: Mini Oral
- Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies
- Moderators:Noboru Yamamoto, Paul J Van Houtte
-
+
MA10.08 - Activated Pathways of Myastenia Gravis in Thymic Epithelial (TETs)
15:17 - 15:22 | Presenter: Jose Carlos Benítez
- Abstract
Loading...
-
+
OA13 - Evolving Epidemiology of Lung Cancer Beyond Tobacco
- 10:45 - 11:45
- 8/09/2022
- Location: Hall C8
- Not for CME Credit
- Type: Oral
- Track: Epidemiology
- Moderators:Matthew T Warkentin, Hilary A Robbins
-
+
OA13.04 - Prevalence of Molecular Alterations in NSCLC and Estimated Indoor Radon in Europe: RADON EUROPE Study
10:57 - 11:07 | Presenter: Miguel Garcia Pardo
- Abstract
Loading...
-
+
OA15 - Patient Selection in Advanced NSCLC Immunotherapy
- 14:30 - 15:30
- 8/09/2022
- Location: Hall C7
- Not for CME Credit
- Type: Oral
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Moderators:Pilar Garrido, António Araújo
-
+
OA15.05 - HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed Phase 2 Study in NSCLC Patients Who Progressed on Anti-PD-(L)1 Therapy
14:52 - 15:02 | Presenter: Benjamin Besse
- Abstract
Loading...
